If it's a sell at this pps , then why bother posting here , Revenue $ 174.43M from last quarter, and now on ph4 Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated, means sales will ramp up .. Either you're short or just want to buy more cheaper shares.
They took out a $220 million flexible loan to buy Treximet at a high rate of 12% and also they have been cash flow negative every quarter.
Turning the company over to the debt holders is about the only way to fix the debt problem leaving the shareholders with nothing.
June 29, 2016
by Dannica Stinson
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)has revealed that its accounts payable, for the year ended 2016-03-31, stands at $37.406 million. The company also provided an update on the accounts payable for the quarter ended 2016-03-31, which amount to $37.406 million. As such, the change in accounts payable for the full year ended 2016-03-31 and quarter ended 2016-03-31 stood at $6.682 million and $6.682 million, respectively.
In addition to this, the company’s deferred tax assets were $6.544 million, for the full year ended 2016-03-31. The figure for the deferred tax assets was $6.544 million, for the quarter ended 2016-03-31.
The company’s asset and liabilities account registered a change of -0.211 millions, for the full year ended 2016-03-31, while a change of $-0.211 million was observed for the quarter ended 2016-03-31.
For the full year ended 2016-03-31, the days sales in receivables stood at 141.0268. The days sales in receivables represents the average number of days it takes for the company to collected the receivables owed by customers. The figure was 141.0268 for the quarterly period ended 2016-03-31.
Furthermore, the accounts receivables for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) registered a movement of $-17.082 million and $-17.082 million, for the full year and quarterly periods, ended 2016-03-31 and 2016-03-31, respectively.
The company’s inventory for the full year ended 2016-03-31 was $0.444 million. Moreover, the figure for the quarter ended 2016-03-31 was $0.444 million.
Outstanding debt was 7.345 million and $7.345 million for the full year ended 2016-03-31 and quarterly period ended 2016-03-31, respectively.
Thanks for the link, next time someone starts pumping treximet I will send them to consumer reports, consumer reports best buy Sumatriptan tablet 100 mg Generic 200 mg $14 $28 $55 you can add in a bottle of Aleve and still cut your bill half.
Too bad all of their drugs are being marketed and they still are far from profitability. In 20 months, Treximet sales will be slashed. This stock has been a gift for the shorts.
Watch and see the debtholders will take the company over and the shareholders will receive nothing.
Why would a company buy this company and assume all of its debt when they can wait a year and buy parts in bankruptcy for pennies on the dollar in about a year without the debt.
With approved drugs... At this price is a gift.
its back on bottom at .45 so should start back up now. may have to wait on earnings report to get going again
Sentiment: Strong Buy
If you aren’t signed up to ULTIMATESTOCKALERTS you need to reconsider trading in general. These guys provide an awesome FREE service and their alerts have made me a boat load of gains in the past. Sign up.
Don't forget, this company has over 300 million in DEBT! This is the reason the stock is at these levels along with declining sales.
I'm in, but will start averaging up with it when it crosses .55. That's what I'm waiting for, some traction.
Sentiment: Strong Buy
Sumatriptan/naproxen sodium 85 mg/500 mg Treximet 170 mg/
$31 $61 $122